Effect of Chlorhexidine-Induced Oral Care on Ventilator-Related Some Respiratory System Complications
NCT04505202
Cross Infection, Disease Attributes
Karabük, Karabük Province, Turkey (Türkiye)
View Trial DetailsNCT Number: NCT04987840
The objective of this study is to evaluate implementation of diagnostic stewardship programs as a strategy to safely reduce antibiotic use, and to generate evidence and tools to support dissemination of diagnostic stewardship programs to a large and diverse group of hospitals.
Interested in participating?
Request InfoAll sexes
Observational
Johns Hopkins Children's Center, Baltimore, Maryland, United States
The Bright STAR Collaborative, or Testing STewardship to reduce Antibiotic Resistance Collaborative, is a prospective multicenter quality improvement (QI) program with the goal of implementing diagnostic stewardship interventions to reduce bacterial culture use as a strategy to reduce antibiotic overuse. Investigators will use data collected by participating sites to determine whether reliable implementation of clinical practice guidelines for evaluation of patients can decrease antibiotic use in pediatric intensive care units. Investigators will perform a quasi-experimental study to compare outcome data in pre- and post- periods.
Greater than or equal to 10 institutions will participate in this collaborative. Participating institutions will develop and implement an evidenced-based clinical decision-making tool as part of their quality improvement (QI) program in their pediatric intensive care unit (PICU).
Specific Aim 1: Evaluate whether locally devised quality improvement programs focused on diagnostic stewardship of respiratory cultures lead to a reduction in respiratory cultures and antibiotic use.
Specific Aim 2: To determine whether these quality improvement initiatives are associated with unintended consequence of patient harm such as mortality, length of stay, readmissions, ventilator associated infections, sepsis and septic shock.
Variables: total respiratory culture rates, culture results, ICU length of stay, mortality rates, hospital and ICU readmission, cause of death, ventilator-associated infection/ventilator-associated condition rate, sepsis, septic shock.
Analysis: The analytic approach equates to estimating and comparing the respiratory culture incidence during the "baseline/pre-implementation" and "post-implementation" periods, using a generalized linear mixed model (GLMM) assuming a Poisson distribution for the monthly number of respiratory cultures with the monthly number of ventilator days as an offset. Similar analyses will be performed for secondary outcomes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: up to 42 months
Rate of endotracheal aspirate cultures; Change in respiratory cultures per 100 ventilator-days per month
Time frame: up to 42 months
Over all use of broad spectrum antibiotics; Total antibiotic days per 1,000 patient days per quarter
Time frame: up to 42 months
Antibiotic days per 1,000 patient-days per month (antibiotic days starting on day 3 of ICU admission)
Time frame: up to 42 months
Death per hospital total ICU admissions comparing pre and post-intervention periods
Time frame: up to 42 months
Days in ICU; median number of days comparing pre and post-intervention periods
Time frame: up to 42 months
Readmission to the ICU within 7 days of discharge. The coordinating center will measure the change in rate of readmission per total ICU admissions comparing pre and post-intervention periods
Time frame: up to 42 months
Readmission to hospital within 7 days of discharge. The coordinating center will measure the change in rate of hospital readmission comparing pre and post-intervention periods
Time frame: up to 42 months
Defined by the following: Rate of ventilator associated infections episodes per 100 ventilator-days per month
Time frame: up to 42 months
defined by the following: International Classification of Diseases (ICD)-10 codes ; Admissions with ICD-10 coded sepsis per total ICU admissions
Time frame: up to 42 months
Defined by the following: ICD-10 codes; Admissions with ICD-10 coded septic shock per total ICU admissions
Johns Hopkins University
Other
Acronym: BrighT STAR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04505202
Cross Infection, Disease Attributes
Karabük, Karabük Province, Turkey (Türkiye)
View Trial DetailsNCT00396578
Cross Infection, Disease Attributes
Stony Brook, New York, United States
View Trial DetailsNCT06000761
Bronchopulmonary Dysplasia, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Gainesville, Florida, United States
View Trial DetailsNCT06113939
Airway Clearance Impairment, Brain Diseases
Madrid, Spain
View Trial Details